Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Topotecan - GlaxoSmithKline

Drug Profile

Topotecan - GlaxoSmithKline

Alternative Names: Hycamtin; NK-211; Nogitecan; NSC 609699; SKF 104864; Topotecan hydrochloride

Latest Information Update: 10 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Developer GlaxoSmithKline; Merck Pharmaceuticals UK; Nippon Kayaku; Novartis; SCRI Development Innovations
  • Class Antineoplastics; Camptothecins; Small molecules
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cervical cancer; Ovarian cancer; Small cell lung cancer
  • Discontinued Brain metastases

Most Recent Events

  • 10 Jul 2019 Discontinued - Phase-III for Brain metastases (Metastatic disease) in Hungary, Poland, Russia, Canada, Slovakia, USA (PO)
  • 08 Aug 2017 Launched for Ovarian cancer in Russia, Ukraine, China, Venezuela, Norway, Israel, Malaysia, Denmark, Turkey, Hong Kong (IV) before August 2017 (IV) (Martindale)
  • 17 May 2016 Launched for Small cell lung cancer (Second- line therapy or later) in Russia, Ukraine, China, Norway, Israel, Switzerland, Hungary, Malaysia, France, Denmark, Turkey, Philippines, Hong Kong, South Africa, Czech Republic, Spain, Brazil, Sweden, Canada, Austria, Argentina, USA, United Kingdom, Chile, Belgium, Germany, Portugal, Australia, New Zealand, Italy, Finland, Greece, Poland, Netherlands, Ireland, Thailand, Singapore before May 2016 (IV) (Martindale)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top